#USA #Chicago #Alzheimer's #Aranscia #Neurogen

Neurogen Biomarking Partners with Aranscia to Combat Alzheimer's Disease

In a significant development for Alzheimer's research and patient care, Neurogen Biomarking has announced a strategic collaboration with Aranscia, a leader in clinical workflow and diagnostic technology solutions. Together, they aim to transform the landscape of early detection for Mild Cognitive Impairment (MCI) and Alzheimer's disease.

The partnership is an exciting fusion of innovation, with Aranscia bringing its award-winning technical and laboratory resources to the table. Central to this collaboration is the AccessDx Laboratory, an Aranscia subsidiary that will provide critical support for Neurogen's pioneering blood-based biomarker tests, which analyze phosphorylated tau (p-tau) 217, a key marker associated with Alzheimer's pathology. This is an essential step forward, as it targets the long-standing challenge of delayed diagnosis in the context of memory-related disorders.

Neurogen's commitment to early detection aligns with a pressing need in the healthcare community. Current statistics indicate that about 7 million Americans aged 65 or older are affected by Alzheimer's, yet an astonishing 92% of those with mild cognitive impairment remain undiagnosed. The slow progression of Alzheimer's often sees its initial signs manifesting unnoticed for years, underscoring the urgent need for innovative solutions. Neurogen's platform represents a paradigm shift, enabling patients to initiate their own diagnostic processes through a user-friendly, patient-initiated model.

As part of this collaboration, Aranscia will also integrate its EMR-agnostic clinical workflow technologies, courtesy of 2bPrecise, which facilitates secure connections and smooth integration of Neurogen's diagnostic outputs across varied healthcare environments. These HIPAA-compliant solutions support thousands of healthcare entities, paving the way for Neurogen's insights to reach a broad audience in a streamlined manner.

Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking, expressed optimism regarding this partnership, stating, "Our driving force is to tackle the issue of delayed detection and diagnosis. By empowering patients within a scientifically validated ecosystem, we aim to guide them thoughtfully along their journey to better brain health." This dedication extends to telehealth services, where board-certified neurologists will assist Neurogen patients, ensuring timely follow-up and facilitating access to cognitive care much more quickly than traditional avenues allow.

The collaboration doesn’t end with these two organizations; it also incorporates other partners like Linus Health, which focuses on cognitive assessment technologies, and Quanterix Corporation, renowned for its ultrasensitive biomarker detection techniques. Such alliances create a robust framework that enhances the overall capabilities of the Neurogen ecosystem.

Looking ahead, the Neurogen platform is set to launch mid-2025, promising access to cutting-edge diagnostic tools for those facing memory and cognitive challenges. This comes at a critical juncture, especially with estimates indicating that nearly 16 million Americans are grappling with memory impairments of various severities.

The implications of this partnership extend beyond mere diagnostics; it represents a holistic approach to patient care that prioritizes early intervention and proactive monitoring. With values centered around innovation, accessibility, and scalable solutions, Neurogen and Aranscia are not only addressing current gaps but also reshaping the future of Alzheimer's care delivery. As Bryon Cipriani, CEO of Aranscia notes, “This partnership exemplifies our commitment to democratizing access to personalized care, positively influencing the lives of countless patients and their families.”

In summary, the Neurogen and Aranscia alliance is a promising step toward a future where Alzheimer's disease can be detected earlier, treated more effectively, and approached with more informed preventive measures. This initiative emphasizes the importance of strategic partnerships in advancing healthcare solutions and enhancing the lives of those affected by cognitive ailments.